Latest Insider Transactions at Avantor, Inc. (AVTR)
This section provides a real-time view of insider transactions for Avantor, Inc. (AVTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avantor, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avantor, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 12
2022
|
Mala Murthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+43.13%
|
-
|
|
May 12
2022
|
Matthew S. Holt Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+45.84%
|
-
|
|
May 12
2022
|
Christi Shaw Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+20.19%
|
-
|
|
May 12
2022
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+21.01%
|
-
|
|
May 04
2022
|
Michael Stubblefield President & CEO |
BUY
Bona fide gift
|
Indirect |
14,500
+3.38%
|
-
|
|
May 04
2022
|
Michael Stubblefield President & CEO |
SELL
Bona fide gift
|
Direct |
14,500
-1.1%
|
-
|
|
Apr 05
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
568
-0.49%
|
$17,608
$31.62 P/Share
|
|
Apr 01
2022
|
John Carethers Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+24.32%
|
-
|
|
Apr 01
2022
|
Michael Severino Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+6.17%
|
-
|
|
Apr 01
2022
|
Gregory L Summe Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+7.04%
|
-
|
|
Apr 01
2022
|
Mala Murthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+36.31%
|
-
|
|
Apr 01
2022
|
Rajiv Gupta Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+0.16%
|
-
|
|
Apr 01
2022
|
Lan Kang Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+18.83%
|
-
|
|
Apr 01
2022
|
Jonathan M Peacock Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+0.71%
|
-
|
|
Apr 01
2022
|
Christi Shaw Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+5.79%
|
-
|
|
Apr 01
2022
|
Juan Andres Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+4.94%
|
-
|
|
Apr 01
2022
|
Joseph R Massaro Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+38.27%
|
-
|
|
Apr 01
2022
|
Matthew S. Holt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,215
+50.0%
|
-
|
|
Mar 01
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
2,027
-1.47%
|
$68,918
$34.47 P/Share
|
|
Feb 25
2022
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,866
-0.6%
|
$275,310
$35.39 P/Share
|
|
Feb 25
2022
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
583
-0.63%
|
$20,405
$35.39 P/Share
|
|
Feb 25
2022
|
Sheri Lewis EVP, Global Ops & Supply Chain |
SELL
Payment of exercise price or tax liability
|
Direct |
1,137
-1.57%
|
$39,795
$35.39 P/Share
|
|
Feb 25
2022
|
Meghan Henson EVP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
931
-2.88%
|
$32,585
$35.39 P/Share
|
|
Feb 25
2022
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
518
-2.75%
|
$18,130
$35.39 P/Share
|
|
Feb 25
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-0.4%
|
$16,345
$35.39 P/Share
|
|
Feb 25
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
2,043
-1.46%
|
$71,505
$35.39 P/Share
|
|
Feb 25
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,043
-0.8%
|
$71,505
$35.39 P/Share
|
|
Feb 25
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.13%
|
$7,560
$35.39 P/Share
|
|
Feb 23
2022
|
Michael Stubblefield President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
69,885
+5.02%
|
-
|
|
Feb 23
2022
|
Justin Miller EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+6.83%
|
-
|
|
Feb 23
2022
|
Sheri Lewis EVP, Global Ops & Supply Chain |
BUY
Grant, award, or other acquisition
|
Direct |
9,822
+11.92%
|
-
|
|
Feb 23
2022
|
Meghan Henson EVP, Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,311
+20.45%
|
-
|
|
Feb 23
2022
|
Steven W Eck SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,138
+21.43%
|
-
|
|
Feb 23
2022
|
Christophe Couturier EVP, AMEA |
BUY
Grant, award, or other acquisition
|
Direct |
6,044
+4.97%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+9.72%
|
-
|
|
Feb 23
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
3,059
-2.39%
|
$100,947
$33.79 P/Share
|
|
Feb 23
2022
|
Thomas A Szlosek EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
16,621
+6.12%
|
-
|
|
Feb 23
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
BUY
Grant, award, or other acquisition
|
Direct |
15,110
+8.24%
|
-
|
|
Feb 20
2022
|
Steven W Eck SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
448
-3.17%
|
$15,232
$34.0 P/Share
|
|
Feb 20
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
398
-0.26%
|
$11,144
$28.69 P/Share
|
|
Feb 20
2022
|
Michael Stubblefield President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,959
-0.87%
|
$372,606
$34.0 P/Share
|
|
Feb 20
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Payment of exercise price or tax liability
|
Direct |
3,072
-2.34%
|
$104,448
$34.0 P/Share
|
|
Feb 20
2022
|
Christophe Couturier EVP, AMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-1.14%
|
$43,078
$34.0 P/Share
|
|
Feb 20
2022
|
Thomas A Szlosek EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,040
-1.67%
|
$137,360
$34.0 P/Share
|
|
Feb 20
2022
|
Justin Miller EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,328
-1.52%
|
$45,152
$34.0 P/Share
|
|
Jan 13
2022
|
Mark Christopher Murray EVP, Biomaterials & AT |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-4.68%
|
$33,966
$37.5 P/Share
|
|
Jan 05
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
11,551
-8.09%
|
$438,938
$38.65 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
SELL
Open market or private sale
|
Direct |
59,418
-29.37%
|
$2,376,720
$40.77 P/Share
|
|
Jan 03
2022
|
Gerard Brophy EVP, Biopharma Production |
BUY
Exercise of conversion of derivative security
|
Direct |
59,418
+22.7%
|
$1,069,524
$18.45 P/Share
|
|
Jan 02
2022
|
Frederic Vanderhaegen EVP, Americas and Europe |
SELL
Payment of exercise price or tax liability
|
Direct |
1,017
-0.66%
|
$42,714
$42.14 P/Share
|